



KDCA

Korea Disease Control and Prevention Agency

# Updates on COVID-19 in Republic of Korea

4 May 2021

## COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
New (1st dose)	66,920	19,795	3,317	2,816	3,487	1,993	2,789	1,513	393
New (1st dose)	30,538	5,033	2,075	1,765	1,810	1,284	510	502	242
Total (1st)	3,466,908	540,404	219,891	148,181	172,001	109,390	98,124	58,988	16,863
Total (2nd)	267,032	41,624	14,185	10,474	19,715	9,689	7,311	10,588	2,731
	Total	Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
New (1st dose)	9,743	1,737	1,248	1,962	1,816	5,698	4,719	2,410	1,484
New (1st dose)	4,987	1,369	1,713	816	2,144	1,755	1,941	1,831	761
Total (1st)	757,351	136,429	130,317	172,549	180,631	206,238	225,742	251,078	42,731
Total (2nd)	43,482	15,415	15,228	13,513	15,082	14,066	10,366	16,549	7,014

※ Figures subject to correction recording update

## Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General <sup>1)</sup>	Anaphylaxis suspected <sup>2)</sup>	Severe suspected <sup>3)</sup>	Deaths
Total	New	3,733,940	858	0.47%	847	5	3	3
	Total		17,485		17,155	179	66	85
AstraZeneca	New	1,864,176	623	0.80%	618	4	1	0
	Total		14,893		14,665	144	37	47
Pfizer	New	1,869,764	235	0.14%	229	1	2	3
	Total		2592		2,490	35	29	38

<sup>1)</sup> Mild cases such as headache, fever, nausea, vomiting, etc.

<sup>2)</sup> Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

<sup>3)</sup> Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases



KDCA

Korea Disease Control and Prevention Agency

# Updates on COVID-19 in Republic of Korea

4 May 2021

## Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		<b>541 (100)</b>	<b>124,269 (100)</b>	<b>239.68</b>
Sex	Male	273 (50.46)	61,879 (49.79)	239.26
	Female	268 (49.54)	62,390 (50.21)	240.10
Age	80 or above	21 (3.88)	5,408 (4.35)	284.75
	70-79	23 (4.25)	8,951 (7.20)	248.15
	60-69	75 (13.86)	19,097 (15.37)	301.01
	50-59	92 (17.01)	23,001 (18.51)	265.39
	40-49	83 (15.34)	18,439 (14.84)	219.79
	30-39	92 (17.01)	16,790 (13.51)	238.32
	20-29	82 (15.16)	18,487 (14.88)	271.61
	10-19	47 (8.69)	8,702 (7.00)	176.14
0-9	26 (4.81)	5,394 (4.34)	130.02	

\* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

## Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		<b>6 (100)</b>	<b>1,840 (100)</b>	<b>1.48</b>	<b>162 (100)</b>
Sex	Male	3 (50.00)	914 (49.67)	1.48	102 (62.96)
	Female	3 (50.00)	926 (50.33)	1.48	60 (37.04)
Age	80 or above	5 (83.33)	1,014 (55.11)	18.75	43 (26.54)
	70-79	1 (16.67)	524 (28.48)	5.85	65 (40.12)
	60-69	0 (0.00)	216 (11.74)	1.13	38 (23.46)
	50-59	0 (0.00)	62 (3.37)	0.27	8 (4.94)
	40-49	0 (0.00)	14 (0.76)	0.08	5 (3.09)
	30-39	0 (0.00)	7 (0.38)	0.04	3 (1.85)
	20-29	0 (0.00)	3 (0.16)	0.02	0 (0.00)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)	

\* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

## AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.21.	4.22.	4.23.	4.24.	4.25.	4.26.	4.27.	4.28.	4.29.	4.30.	5.1	5.2.	5.3.	5.4.
<b>Total</b>	116	125	127	136	136	132	156	160	157	164	174	170	164	162

\* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)